Evidence map›Paper›PMID 37493818›Full record

ArticleBiomedical microdevices2023

A standard 96-well based high throughput microfluidic perfusion biofilm reactor for in situ optical analysis.

David McLeod, Lai Wei, Zhenyu Li

Open access · greenAbstract read
In one paragraph

Article in Biomedical microdevices, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

David McLeod *Department of Biomedical Engineering, The George Washington University, 800 22nd St NW, Washington, DC, USA.
Lai Wei *Department of Biomedical Engineering, The George Washington University, 800 22nd St NW, Washington, DC, USA.
Zhenyu LiDepartment of Biomedical Engineering, The George Washington University, 800 22nd St NW, Washington, DC, USA. zhenyu@gwu.edu.
George Washington University · US

Funding

Scalable platform for optimizing human cardiac tissue engineering via optical pacing and on-demand oxygenationR01HL144157 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI ENTCHEVA, EMILIA, KAY, MATTHEW W. · 2019 to 2022
$2.8M
NHLBI NIH HHS R01 HL144157
6 · The paper itself

Abstract

Biofilm infections represent a major public health threat due to their high tolerance to antimicrobials and the lack of specific anti-biofilm drugs. To develop such drugs, it is crucial to have high-throughput biofilm growth systems that can emulate in vivo conditions without the cost and complexity of animal models. However, no current biofilm reactor can provide in vivo-like conditions in a high throughput standard microtiter format. This paper demonstrates a novel high-throughput (HT) microfluidic perfusion biofilm reactor (HT-μPBR) compatible with a standard 96-well microtiter plate for in situ optical analysis. A snap-on liquid-tight cover for standard microtiter plates was designed and fabricated with fluidic channels to provide closed-loop recirculating perfusion. Our system takes steps toward providing in vivo-like conditions with controlled shear stress and nutrient delivery. We describe the system fabrication and usage in optical analysis of biomass and viability of Escherichia coli (E. coli) biofilms. The HT-μPBR was set to perfuse at 1 mL/min corresponding to an average shear rate of approximately [Formula: see text] on the bottom surface of a single well. Biofilms were detected on well plate bottoms and measured using a fluorescence microscope and plate reader to determine biomass and viability. Samples cultured in the HT-μPBR showed increased biomass while maintaining viability after 24 h. The HT-μPBR can further be combined with HT antibiotic susceptibility testing and additional optical techniques such as time-lapse imaging to improve understanding of the drug reaction mechanism as well as the optimization of drug combinations and delivery profiles.

Indexed as

Escherichia coliMicrofluidicsAnimalsBiofilmsPerfusionBiofilmBioreactorFabricationMicrofluidicPerfusion

Identifiers

PMID37493818
PMCPMC12614770
OpenAlexW4385264496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.